Global Pharma, Biotech and Diagnostics Royalty Financing Partnering Directory 2018

DUBLIN, March 16, 2018 /PRNewswire/ --

The "Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product

Revenue assets - also known as synthetic royalties', where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.

Key benefits

• In-depth understanding of royalty financing partnering deal trends since 2010
• Analysis of the structure of royalty financing partnering agreements with numerous real life case studies
• Comprehensive listing of all royalty financing deals since 2010, together with deal terms, value and press release
• Comprehensive access to actual royalty financing partnering contracts entered into by the world's biopharma companies
• Insight into the terms included in a royalty financing partnering agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 includes:

• Trends in royalty financing dealmaking in the biopharma industry since 2010
• Analysis of royalty financing deal structure
• Case studies of real-life royalty financing deals
• Comprehensive listing of royalty financing deals since 2010
• Access to royalty financing contract documents
• The leading royalty financing deals by value since 2010
• Most active royalty financing dealmakers since 2010
• The leading royalty financing partnering resources

Available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in royalty financing dealmaking

2.1. Introduction
2.2. Difference between royalty and revenue financing deals
2.3. Trends in royalty financing deals since 2010
2.3.1. Royalty financing dealmaking by year, 2010 to 2018
2.3.2. Royalty financing dealmaking by industry sector, 2010 to 2018
2.3.3. Royalty financing dealmaking by therapy area, 2010 to 2018
2.3.4. Royalty financing dealmaking most active, 2010 to 2018
2.4. Reasons for entering into royalty financing partnering deals
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.2. Recent royalty asset purchase deals
2.5.3. The role of big pharma in royalty buyback
2.5.4. The future of royalty asset purchase deals

Chapter 3 - Overview of royalty financing structure

3.1. Introduction
3.2. Anatomy of a royalty asset purchase agreement
3.3. Example royalty financing agreements
3.3.1. Case study 1: Xoma - UCB - Orbimed Advisors
3.3.2. Case study 2: Dyax - Paul Capital Healthcare
3.3.3. Case study 3: Royalty financing: Biocryst Pharmaceuticals -Shionogi
3.3.4. Case study 4: Royalty asset: TPG - CV Therapeutics

Chapter 4 - Leading royalty financing deals

4.1. Introduction
4.2. Top royalty financing deals by value

Chapter 5 - Top 10 most active royalty financing dealmakers

5.1. Introduction
5.2. Top 10 most active royalty financing dealmakers

Chapter 6 - Royalty financing contract documents 2010- 2018

Chapter 7 - Royalty financing agreement directory 2010- 2018

7.1. Introduction
7.2. Company A-Z
7.3. By industry sector
7.4. By therapy area

For more information about this report visit https://www.researchandmarkets.com/research/qfcszs/global_pharma?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com